158 related articles for article (PubMed ID: 30973679)
1. Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer.
Basile A; De Marco M; Festa M; Falco A; Iorio V; Guerriero L; Eletto D; Rea D; Arra C; Lamolinara A; Ballerini P; Damiani V; Rosati A; Sala G; Turco MC; Marzullo L; De Laurenzi V
Mol Oncol; 2019 Jun; 13(6):1388-1399. PubMed ID: 30973679
[TBL] [Abstract][Full Text] [Related]
2. BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration.
Dufrusine B; Damiani V; Capone E; Pieragostino D; Dainese E; De Marco M; Reppucci F; Turco MC; Rosati A; Marzullo L; Sala G; Sallese M; De Laurenzi V
J Cell Biochem; 2022 Jan; 123(1):65-76. PubMed ID: 34741485
[TBL] [Abstract][Full Text] [Related]
3. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages.
Rosati A; Basile A; D'Auria R; d'Avenia M; De Marco M; Falco A; Festa M; Guerriero L; Iorio V; Parente R; Pascale M; Marzullo L; Franco R; Arra C; Barbieri A; Rea D; Menichini G; Hahne M; Bijlsma M; Barcaroli D; Sala G; di Mola FF; di Sebastiano P; Todoric J; Antonucci L; Corvest V; Jawhari A; Firpo MA; Tuveson DA; Capunzo M; Karin M; De Laurenzi V; Turco MC
Nat Commun; 2015 Nov; 6():8695. PubMed ID: 26522614
[TBL] [Abstract][Full Text] [Related]
4. BAG3 deletion suppresses stem cell-like features of pancreatic ductal adenocarcinoma via translational suppression of ISG15.
Li XY; Yan J; Sun J; Li C; Jiang JY; Wang JM; Meng XN; Liang JJ; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2019 May; 1866(5):819-827. PubMed ID: 30771383
[TBL] [Abstract][Full Text] [Related]
5. Role of BAG3 in cancer progression: A therapeutic opportunity.
De Marco M; Basile A; Iorio V; Festa M; Falco A; Ranieri B; Pascale M; Sala G; Remondelli P; Capunzo M; Firpo MA; Pezzilli R; Marzullo L; Cavallo P; De Laurenzi V; Turco MC; Rosati A
Semin Cell Dev Biol; 2018 Jun; 78():85-92. PubMed ID: 28864347
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6.
Aguilar EN; Sagar S; Murray BR; Rajesh C; Lei EK; Michaud SA; Goodlett DR; Caffrey TC; Grandgenett PM; Swanson B; Brooks TM; Black AR; van Faassen H; Hussack G; Henry KA; Hollingsworth MA; Brooks CL; Radhakrishnan P
Mol Cancer Ther; 2024 Jun; 23(6):836-853. PubMed ID: 38394685
[TBL] [Abstract][Full Text] [Related]
7. BAG3 regulates stability of IL-8 mRNA via interplay between HuR and miR-4312 in PDACs.
Li C; Jiang JY; Wang JM; Sun J; An MX; Li S; Yan J; Wang HQ
Cell Death Dis; 2018 Aug; 9(9):863. PubMed ID: 30154469
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease.
Kirk JA; Cheung JY; Feldman AM
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396980
[TBL] [Abstract][Full Text] [Related]
9. BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.
Falco A; Rosati A; Festa M; Basile A; De Marco M; d'Avenia M; Pascale M; Dal Piaz F; Tavano F; Di Mola FF; di Sebastiano P; Berloco PB; Nudo F; Caraglia M; Febbraro A; Barcaroli D; Scarpa A; Pezzilli R; De Laurenzi V; Turco MC
Am J Gastroenterol; 2013 Jul; 108(7):1178-80. PubMed ID: 23821002
[No Abstract] [Full Text] [Related]
10. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.
Rosati A; Bersani S; Tavano F; Dalla Pozza E; De Marco M; Palmieri M; De Laurenzi V; Franco R; Scognamiglio G; Palaia R; Fontana A; di Sebastiano P; Donadelli M; Dando I; Medema JP; Dijk F; Welling L; di Mola FF; Pezzilli R; Turco MC; Scarpa A
Am J Pathol; 2012 Nov; 181(5):1524-9. PubMed ID: 22944597
[TBL] [Abstract][Full Text] [Related]
11. A synthetic anti-Frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties.
Pavlovic Z; Adams JJ; Blazer LL; Gakhal AK; Jarvik N; Steinhart Z; Robitaille M; Mascall K; Pan J; Angers S; Moffat J; Sidhu SS
MAbs; 2018; 10(8):1157-1167. PubMed ID: 30183492
[TBL] [Abstract][Full Text] [Related]
12. Lutein induces an inhibitory effect on the malignant progression of pancreatic adenocarcinoma by targeting BAG3/cholesterol homeostasis.
Han L; Song X
J Biochem Mol Toxicol; 2022 Feb; 36(2):e22958. PubMed ID: 34783111
[TBL] [Abstract][Full Text] [Related]
13. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
14. A newly developed anti-Mucin 13 monoclonal antibody targets pancreatic ductal adenocarcinoma cells.
Nishii Y; Yamaguchi M; Kimura Y; Hasegawa T; Aburatani H; Uchida H; Hirata K; Sakuma Y
Int J Oncol; 2015 Apr; 46(4):1781-7. PubMed ID: 25672256
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model.
Li P; Rozich N; Wang J; Wang J; Xu Y; Herbst B; Yu R; Muth S; Niu N; Li K; Funes V; Gai J; Osipov A; Edil BH; Wolfgang CL; Lei M; Liang T; Zheng L
Cancer Lett; 2022 Jul; 539():215722. PubMed ID: 35533951
[TBL] [Abstract][Full Text] [Related]
16. A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.
Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203331
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
[TBL] [Abstract][Full Text] [Related]
18. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
[TBL] [Abstract][Full Text] [Related]
19. Macrophages and pancreatic ductal adenocarcinoma.
Habtezion A; Edderkaoui M; Pandol SJ
Cancer Lett; 2016 Oct; 381(1):211-6. PubMed ID: 26708507
[TBL] [Abstract][Full Text] [Related]
20. A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
O'Sullivan D; Dowling P; Joyce H; McAuley E; McCann A; Henry M; McGovern B; Barham P; Kelleher FC; Murphy J; Kennedy S; Swan N; Moriarty M; Clynes M; Larkin A
Br J Cancer; 2017 Oct; 117(9):1326-1335. PubMed ID: 28881357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
